Autoimmunity and cancer.

No abstract is available for this paper.

• Publication year

  2021

• Venue

  Autoimmunity Reviews

• Publication date

  2021-07-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.autrev.2021.102882PMID 34229048
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy

  2021cited by this paper
• Rheumatic immune-related adverse events associated with cancer immunotherapy: A nationwide multi-center cohort.

  2020cited by this paper
• Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: A meta-analysis of observational studies.

  2020cited by this paper
• Eight pillars of oncorheumatology: Crossroads between malignancies and musculoskeletal diseases.

  2020cited by this paper
• Clinical characteristics and prognosis of polymyositis and dermatomyositis associated with malignancy: a 25-year retrospective study

  2019cited by this paper
• Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapies

  2019cited by this paper
• Systemic lupus erythematosus: Diagnosis and clinical management.

  2019cited by this paper
• Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies.

  2019cited by this paper
• 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

  2019cited by this paper
• Increased Incidental Thyroid Cancer in Patients With Subclinical Chronic Lymphocytic Thyroiditis.

  2019cited by this paper
• Systemic lupus erythematosus and lymphoma: Incidence, pathogenesis and biology.

  2018cited by this paper
• Evidence supports blind screening for internal malignancy in dermatomyositis

  2018cited by this paper
• Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.

  2018cited by this paper
• Relationship between Hashimoto's thyroiditis and papillary thyroid carcinoma in children and adolescents.

  2018cited by this paper
• The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis

  2018cited by this paper
• Cancer and autoimmune diseases.

  2017cited by this paper
• Hashimoto's thyroiditis – an independent risk factor for papillary carcinoma

  2017cited by this paper
• Risk of Malignancy in Dermatomyositis and Polymyositis

  2017cited by this paper
• Methotrexate treatment and risk for cutaneous malignant melanoma: a retrospective comparative registry‐based cohort study

  2017cited by this paper
• Thymoma associated with autoimmune diseases: 85 cases and literature review.

  2016cited by this paper
• Systemic lupus erythematosus diagnosis and management

  2016cited by this paper
• Features of childhood Sjögren's syndrome in comparison to adult Sjögren's syndrome: considerations in establishing child-specific diagnostic criteria.

  2016cited by this paper
• Clinical picture, outcome and predictive factors of lymphoma in Sjӧgren syndrome.

  2015cited by this paper
• Predicting the Outcome of Sjogren’s Syndrome-Associated Non-Hodgkin’s Lymphoma Patients

  2015cited by this paper
• Polymyositis/dermatomyositis and Malignancy Risk: A Metaanalysis Study

  2015cited by this paper
• Primary CNS lymphoproliferative disease, mycophenolate and calcineurin inhibitor usage

  2015cited by this paper
• Review: Cancer‐Induced Autoimmunity in the Rheumatic Diseases

  2015cited by this paper
• Polymyositis and dermatomyositis as a risk of developing cancer

  2015cited by this paper
• Cancer and scleroderma: a paraneoplastic disease with implications for malignancy screening

  2015cited by this paper
• Systemic Lupus Erythematous and Malignancy Risk: A Meta-Analysis

  2015cited by this paper
• Control of Regulatory T Cell Migration, Function, and Homeostasis

  2015cited by this paper
• Lymphoma development in patients with autoimmune and inflammatory disorders--what are the driving forces?

  2014cited by this paper
• Factors Predicting Malignancy in Patients with Polymyositis and Dermatomyostis: A Systematic Review and Meta-Analysis

  2014cited by this paper
• Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus

  2014cited by this paper
• Homeostasis and function of regulatory T cells (Tregs) in vivo: lessons from TCR-transgenic Tregs

  2014cited by this paper
• Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer

  2014cited by this paper
• A retrospective study of long-term outcomes in 152 patients with primary Sjogren's syndrome: 25-year experience.

  2014cited by this paper
• Incidence and predictive factors for malignancies with dermatomyositis: a cohort from southern China.

  2014cited by this paper
• Increased incidence of squamous cell carcinoma of the skin after long‐term treatment with azathioprine in patients with auto‐immune inflammatory rheumatic diseases

  2014cited by this paper
• Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis

  2014cited by this paper
• Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: a meta-analysis of prospective cohort studies.

  2014cited by this paper
• Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked?

  2014cited by this paper
• Identification of lymphoma predictors in patients with primary Sjögren’s syndrome: a systematic literature review and meta-analysis

  2014cited by this paper
• Dermatomyositis associated with hepatitis B virus-related hepatocellular carcinoma

  2014cited by this paper
• Risk of malignancy associated with biologic agents in pediatric rheumatic disease

  2014cited by this paper
• Clinical features distinguishing lymphoma development in primary Sjögren's Syndrome--a retrospective cohort study.

  2013cited by this paper
• Malignancy and Idiopathic Inflammatory Myopathies

  2013cited by this paper
• Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.

  2013cited by this paper
• What is the Background Incidence of Malignancy in Children with Rheumatic Disease?

  2013cited by this paper
• Primary Sjögren's syndrome and malignancy risk: a systematic review and meta-analysis

  2013cited by this paper
• Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results.

  2012cited by this paper
• American College of Rheumatology classification criteria for Sjögren's syndrome: A data‐driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance Cohort

  2012cited by this paper
• Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.

  2012cited by this paper
• Rheumatology and oncology: an updated review of rheumatic manifestations of malignancy and anti-neoplastictherapy.

  2012cited by this paper
• Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis.

  2012cited by this paper
• A Clinical Prediction Rule for Lymphoma Development in Primary Sjögren’s Syndrome

  2012cited by this paper
• Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents

  2012cited by this paper
• Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins.

  2012cited by this paper
• High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort.

  2011cited by this paper
• Report on malignancies in the German juvenile idiopathic arthritis registry.

  2011cited by this paper
• Malignancies in Juvenile Idiopathic Arthritis: A Preliminary Report

  2011cited by this paper
• Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.

  2010cited by this paper
• Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.

  2010cited by this paper
• Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration.

  2010cited by this paper
• Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan

  2010cited by this paper
• Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.

  2010cited by this paper
• Juvenile idiopathic arthritis and risk of cancer: a nationwide cohort study.

  2010cited by this paper
• Hematologic Manifestations and Predictors of Lymphoma Development in Primary Sjögren Syndrome: Clinical and Pathophysiologic Aspects

  2009cited by this paper
• Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I.

  2008cited by this paper
• Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register

  2008cited by this paper
• Immunotherapy of autoimmunity and cancer: the penalty for success

  2008cited by this paper
• Malignancy and rheumatoid arthritis

  2007cited by this paper
• Juvenile idiopathic arthritis.

  2007cited by this paper
• Persistent chronic inflammation contributes to the development of cancer in patients with rheumatoid arthritis from a defined population of northwestern Spain.

  2007cited by this paper
• Oncogenic inflammation and autoimmune disease.

  2006cited by this paper
• Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.

  2004cited by this paper
• Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population.

  2003cited by this paper
• Clinical and Imaging Findings of Lymphoma in Patients with Sjögren Syndrome

  2003cited by this paper
• NF-kappaB in cancer: from innocent bystander to major culprit.

  2002cited by this paper
• Malignant lymphoma in primary Sjogren's syndrome.

  2001cited by this paper
• Inflammation and cancer: back to Virchow?

  2001cited by this paper
• Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study.

  2001cited by this paper
• Clinical evolution, and morbidity and mortality of primary Sjögren's syndrome.

  2000cited by this paper
• The overall and temporal association of cancer with polymyositis and dermatomyositis.

  1994cited by this paper

• Autoimmune disease-associated lymphomas: research progress and review

  2026cites this paper
• A multi-omics features-based approach integrating immunogenicity and inflammation enhances immunotherapy benefit in clear cell renal cell carcinoma

  2026cites this paper
• Mortality and Survival Analysis in Patients With Cancer Occurrence After Sjögren's Syndrome: A Long‐Term Cohort Study in China

  2025cites this paper
• Autoimmune diseases and risk of gastrointestinal cancer: an umbrella review of meta-analyses of observational studies.

  2025cites this paper
• Risk relationship between six autoimmune diseases and malignancies: An umbrella review.

  2025cites this paper
• Refractory Nodular Scleritis as a Presenting Sign of Colorectal Cancer

  2025cites this paper
• Knockdown of TIM3 Hampers Dendritic Cell Maturation and Induces Immune Suppression by Modulating T-Cell Responses

  2025cites this paper
• Higher healthcare use before paediatric multiple sclerosis onset: a nationwide cohort study

  2025cites this paper
• Cancer in connective tissue disease

  2025cites this paper
• Advances and perspectives on isolation, structural characterization, structure-property relationships, and pharmacological mechanisms of tumor immune glucans: A review.

  2025cites this paper
• Case report of concurrent ulcerative colitis and bilateral breast cancer: a literature review of the bidirectional association between autoimmune diseases and breast cancer

  2025cites this paper
• Incidence and relative risk of colorectal cancer in autoimmune diseases: a global pooled-analysis with more than 91 million participants

  2025cites this paper
• Multiple Sklerose und Onkologie: Neue Perspektiven an der Schnittstelle zweier Disziplinen

  2025cites this paper
• Evaluating the risk of digestive system cancer in autoimmune disease patients: a systematic review and meta-analysis focusing on bias assessment

  2025cites this paper
• Cancer Risk in Autoimmune and Immune-Mediated Diseases: A Narrative Review for Practising Clinicians

  2025cites this paper
• Severe Toxicities From Definitive Chemoradiotherapy for Oropharyngeal Cancer in a Patient With Comorbid Sjögren’s Syndrome

  2025cites this paper
• Maladaptation diseases as disorders of intraorganismal individuation

  2025cites this paper
• Association of different autoimmune diseases with gastric cancer incidence and risk: an up-to-date global population-based analysis.

  2025cites this paper
• SPP1, LYZ, and MCM5: potential diagnostic biomarkers for rheumatoid arthritis and cervical cancer comorbidity

  2025cites this paper
• Inflammation Beyond the Prostate: The Role of Systemic Inflammatory Disorders in Prostate Carcinogenesis

  2025cites this paper
• Advances in the structure and function of the nucleolar protein fibrillarin

  2024cites this paper
• Immunosuppressive role of benzo[a]pyrene exposure in prostate cancer progression.

  2024cites this paper
• Autoimmune diseases and risk of non-Hodgkin lymphoma: A Mendelian randomisation study

  2024cites this paper
• The Underestimated Impact of Hashimoto Thyroiditis on Thyroid Papillary Carcinoma

  2024cites this paper
• Autoimmune diseases and the risk of bladder cancer: A Mendelian randomization analysis.

  2024cites this paper
• Treatment of Autoimmune Rheumatic Disease and the Risk of Malignancy

  2024influential citation
• Malignant transformation of oral lichen planus: where are we now?

  2024cites this paper
• Autoimmune Diseases and Risk of Non‐Hodgkin Lymphoma: A Mendelian Randomisation Study

  2024cites this paper
• Potential medicinal value of N6‐methyladenosine in autoimmune diseases and tumours

  2023cites this paper
• Malignancies in systemic rheumatic diseases: A mini review

  2023cites this paper
• Transcriptome sequencing reveals novel molecular features of SLE severity

  2023cites this paper
• Paraneoplastic autoimmune Laminin-332 syndrome (PALS): Anti-Laminin-332 mucous membrane pemphigoid as a prototype.

  2023cites this paper
• Increased prevalences of head and neck cancers in patients with Sjögren's syndrome

  2023cites this paper
• Risk of thyroid cancer among patients with vitiligo: A systematic review and meta-analysis

  2023cites this paper
• Expression of Autoimmunity-Related Genes in Melanoma

  2022cites this paper
• Autoimmune complications of COVID-19 and potential consequences for long-lasting disease syndromes

  2022cites this paper
• PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases

  2022cites this paper
• COVID-19 vs. Cancer Immunosurveillance: A Game of Thrones within an Inflamed Microenviroment

  2022cites this paper